NEW YORK–(BUSINESS WIRE)–Rocket
Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading
U.S.-based multi-platform clinical-stage gene therapy company, today
announces that Gaurav Shah, M.D., Chief Executive Officer and President
of Rocket is scheduled to present on Wednesday, May 15, 2019, at
3:40p.m. Pacific Time at the Bank of America Merrill Lynch 2019
Healthcare Conference in Las Vegas, Nevada.
Gaurav Shah, M.D. will also participate in a Gene Therapy Panel on Wednesday,
May 15, 2019, at 4:20p.m. Pacific Time
A live audio webcast of the presentation will be available on the
Investors section of the company’s website, www.rocketpharma.com.
A replay of the presentation will be archived on the Rocket website
following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket’s lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Rocket’s additional pipeline programs for bone
marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD),
Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant
Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy
program for a devastating, pediatric heart failure indication, Danon
disease. For more information about Rocket, please visit www.rocketpharma.com.
Contacts
Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
Rocket
Pharma, Inc.
The Empire State Building, Suite 7530
New York,
NY 10118
www.rocketpharma.com
[email protected]
